Strongest cannabinoid evidence — FDA-approved CBD (Epidiolex) for Dravet and LGS
Epilepsy represents the strongest clinical evidence base for any cannabinoid. CBD (Epidiolex) received FDA approval in 2018 for Dravet syndrome and Lennox-Gastaut syndrome — the first cannabis-derived pharmaceutical approval in US history. Multiple Phase III RCTs demonstrate significant seizure reduction, establishing CBD as a legitimate anticonvulsant for treatment-resistant epilepsy.
Medical Disclaimer: Epilepsy treatment requires specialist supervision. Never stop antiseizure medications without medical guidance. CBD has significant drug interactions with many antiseizure medications.
Epilepsy affects 50 million people worldwide, and approximately 30% have treatment-resistant epilepsy (TRE) — seizures that do not respond to two or more antiseizure medications. For these patients, options are limited and quality of life is severely impaired. CBD's anticonvulsant mechanisms are distinct from conventional antiseizure drugs and include: GPR55 antagonism (reducing neuronal hyperexcitability), modulation of voltage-gated sodium channels, TRPV1 desensitization, and adenosine reuptake inhibition (increasing inhibitory adenosine tone). The pivotal GWPCARE1 and GWPCARE2 trials for Dravet syndrome showed CBD (20mg/kg/day) reduced convulsive seizure frequency by 39% vs. 13% for placebo. The GWPCARE3 and GWPCARE4 trials for LGS showed CBD reduced drop seizure frequency by 37–42% vs. 17–21% for placebo. In 2020, FDA also approved Epidiolex for tuberous sclerosis complex (TSC). THC has anticonvulsant properties in animal models but is not used clinically due to psychoactivity and potential proconvulsant effects at high doses.
Evidence summary for cannabinoid-based interventions in Epilepsy.
Mechanism: GPR55 antagonism, voltage-gated sodium channel modulation, TRPV1 desensitization, adenosine reuptake inhibition — mechanisms distinct from conventional antiseizure drugs
Clinical Status: FDA-approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex (2018–2020)
Approved dose: 2.5–20mg/kg/day. Significant drug interactions: CBD inhibits CYP2C19 and CYP3A4, increasing levels of clobazam (active metabolite N-desmethylclobazam). Liver enzyme elevation in ~5–20% of patients. Most evidence is for pharmaceutical-grade CBD (Epidiolex), not commercial CBD products.
Mechanism: CB1 receptor modulation of neuronal excitability; anticonvulsant in animal models
Clinical Status: Not used clinically for epilepsy; potential proconvulsant at high doses
THC has anticonvulsant properties in animal models but is not recommended for epilepsy due to psychoactivity, potential proconvulsant effects, and lack of clinical evidence.
Mechanism: CB1 antagonism and CB2 partial agonism; anticonvulsant in multiple mouse seizure models
Clinical Status: Preclinical only; no completed human trials for epilepsy
THCV showed anticonvulsant effects in Dravet syndrome mouse models. May act synergistically with CBD. No human clinical data available.
Peer-reviewed research on cannabinoids and Epilepsy.
Devinsky O, Cross JH, Laux L, et al. · New England Journal of Medicine
CBD (20mg/kg/day) reduced convulsive seizure frequency by 39% vs. 13% for placebo in Dravet syndrome patients (median reduction). 5% of CBD patients became seizure-free vs. 0% placebo.
View on DOI.orgDevinsky O, Marsh E, Friedman D, et al. · The Lancet Neurology
Open-label trial of CBD in 137 patients with treatment-resistant epilepsy showed median 36.5% reduction in monthly motor seizures. Adverse events included somnolence, decreased appetite, and diarrhea.
View on DOI.orgDevinsky O, Patel AD, Cross JH, et al. · Neurology
Both 10mg/kg/day and 20mg/kg/day CBD doses significantly reduced convulsive seizures vs. placebo in Dravet syndrome, with the higher dose showing greater efficacy.
View on DOI.orgYes. Epidiolex (pharmaceutical-grade CBD) is FDA-approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. It is the first cannabis-derived drug approved by the FDA. Commercial CBD products are not approved for epilepsy and have not been tested in the same rigorous trials.
The strongest evidence is for Dravet syndrome and Lennox-Gastaut syndrome — both severe, treatment-resistant childhood epilepsies. Evidence for other epilepsy types is more limited. CBD is generally considered for treatment-resistant epilepsy after conventional antiseizure medications have failed.
Yes — this is critical. CBD inhibits CYP2C19 and CYP3A4 enzymes, increasing blood levels of many antiseizure medications including clobazam, valproate, and others. CBD can cause liver enzyme elevation, particularly when combined with valproate. Careful monitoring and dose adjustments are required.
Commercial CBD products are not equivalent to Epidiolex. They vary widely in CBD content, purity, and bioavailability. Epidiolex is pharmaceutical-grade, precisely dosed, and tested in rigorous clinical trials. Using commercial CBD for epilepsy without medical supervision is not recommended.
